Read by QxMD icon Read

BDNF mood disorders

Chin-Chuen Lin, Chien-Te Lee, Ya-Ting Lo, Tiao-Lai Huang
BACKGROUND: Brain-derived neurotrophic factor (BDNF) protein or mRNA levels may be involved in the pathophysiology of bipolar disorder. However, the results were inconsistent. We aimed to simultaneously investigate the relationship of BDNF protein and mRNA levels in peripheral blood of patients with bipolar mania. METHODS: Patients with bipolar mania (n = 30) and healthy controls (n = 30) were recruited during our one-year study. Psychiatric diagnoses were made according to Diagnostic and Statistical Manual of Mental Disorders, 4th Edition criteria...
August 2016: Biomedical Journal
Hang Xu, Yu Zhang, Fan Zhang, San-Na Yuan, Feng Shao, Weiwen Wang
Early stress is a significant risk factor for the onset of mood disorders such as depression during adulthood. Impairments in cognitive flexibility mediated by prefrontal cortex (PFC) dysfunction are increasingly recognized as important etiological and pathological factors in the development of depression. Our previous study demonstrated that social defeat stress during early adolescence produced delayed deficits in cognitive flexibility in adult mice. The potential molecular mechanisms underlying these long-term consequences remain unclear...
2016: Frontiers in Molecular Neuroscience
Iva Dincheva, Niccola B Lynch, Francis S Lee
Brain-derived neurotrophic factor (BDNF) is a growth factor that is dynamically expressed in the brain across postnatal development, regulating neuronal differentiation and synaptic plasticity. The neurotrophic hypothesis of psychiatric mood disorders postulates that in the adult brain, decreased BDNF levels leads to altered neural plasticity, contributing to disease. Although BDNF has been established as a key factor regulating the critical period plasticity in the developing visual system, it has recently been shown to also play a role in fear circuitry maturation, which has implications for the emergence of fear-related mood disorders...
October 2016: Depression and Anxiety
Jacob D Meyer, Kelli F Koltyn, Aaron J Stegner, Jee-Seon Kim, Dane B Cook
OBJECTIVE: Brain-derived neurotrophic factor (BDNF) has recently emerged as one potential mechanism with which exercise improves mood in major depressive disorder (MDD). This study examined the relationship between changes in serum total BDNF and mood following acute exercise in MDD. It was hypothesized that acute exercise would increase BDNF in an intensity-dependent manner and that changes in BDNF would be significantly related to improvement in depressed mood post-exercise. METHODS: Twenty-four women (age: 38...
September 28, 2016: Psychoneuroendocrinology
Maj Vinberg
This study investigated a high-risk sample in order to elucidate risk factors for affective disorder. Healthy monozygotic (MZ) and dizygotic (DZ) twins with and without a co-twin with a history of affective disorder were identified through nationwide registers. Two risk groups were identified: the high-risk group comprised twins at risk of developing affective disorder (DZ or MZ twin; index co-twin affected); the low risk group (control group) comprised twins at low risk of developing affective disorder (DZ or MZ twin; index co-twin not affected)...
October 2016: Danish Medical Journal
Rachel Puralewski, Georgia Vasilakis, Marianne L Seney
BACKGROUND: Women are twice as likely to be diagnosed with major depressive disorder (MDD) compared to men, but the molecular mechanisms underlying this sex difference are unclear. Previous studies in the human postmortem brain suggest dysfunction in basolateral amygdala (BLA) inhibitory gamma-aminobutyric acid (GABA) signaling and brain-derived neurotrophic factor (BDNF) function, specifically in females with MDD. METHODS: We investigated the effects of sex chromosome complement, developmental gonadal sex, and circulating testosterone on expression of 3 GABA-related and 2 BDNF-related genes in the BLA using three cohorts of four core genotypes (FCG) mice...
2016: Biology of Sex Differences
Alma Y Galvez-Contreras, Tania Campos-Ordonez, Veronica Lopez-Virgen, Jesus Gomez-Plascencia, Rodrigo Ramos-Zuniga, Oscar Gonzalez-Perez
The psychiatric disorders are one of the most disabling illnesses in the world and represent a major problem for public health. These disorders are characterized by neuroanatomical or biochemical changes and it has been suggested that such changes may be due to inadequate neurodevelopment. Diverse alterations in the gene expression and/or serum level of specific growth factors have been implicated in the etiology, symptoms and progression of some psychiatric disorders. Herein, we summarize the latest information regarding the role of brain-derived neurotrophic factor (BDNF), epidermal growth factor (EGF), fibroblast growth factor (FGF), Insulin-like growth factor (IGF-1), neuroregulin-1 (NGR-1), erythropoietin (EPO), vascular growth factor (VEGF), transforming growth factor beta (TGF-β), nerve growth factor (NGF) and others cytokines in the pathogenesis of schizophrenia, depression, bipolar and anxiety disorders...
December 2016: Cytokine & Growth Factor Reviews
L Zhou, S L Ma, P K K Yeung, Y H Wong, K W K Tsim, K F So, L C W Lam, S K Chung
Intracellular cAMP and serotonin are important modulators of anxiety and depression. Fluoxetine, a selective serotonin reuptake inhibitor (SSRI) also known as Prozac, is widely used against depression, potentially by activating cAMP response element-binding protein (CREB) and increasing brain-derived neurotrophic factor (BDNF) through protein kinase A (PKA). However, the role of Epac1 and Epac2 (Rap guanine nucleotide exchange factors, RAPGEF3 and RAPGEF4, respectively) as potential downstream targets of SSRI/cAMP in mood regulations is not yet clear...
2016: Translational Psychiatry
Barbara M L C Bocco, João Pedro Werneck-de-Castro, Kelen C Oliveira, Gustavo W Fernandes, Tatiana L Fonseca, Bruna P P Nascimento, Elizabeth A McAninch, Esther Ricci, Zsuzsanna Kvárta-Papp, Csaba Fekete, Maria Martha Bernardi, Balázs Gereben, Antonio C Bianco, Miriam O Ribeiro
Millions of levothyroxine-treated hypothyroid patients complain of impaired cognition despite normal TSH serum levels. This could reflect abnormalities in the type 2 deiodinase (D2)-mediated T4-to-T3 conversion, given their much greater dependence on the D2 pathway for T3 production. T3 normally reaches the brain directly from the circulation or is produced locally by D2 in astrocytes. Here we report that mice with astrocyte-specific Dio2 inactivation (Astro-D2KO) have normal serum T3 but exhibit anxiety-depression-like behavior as found in open field and elevated plus maze studies and when tested for depression using the tail-suspension and the forced-swimming tests...
September 2016: Endocrinology
Eero Castrén, Masami Kojima
Levels of brain-derived neurotrophic factor (BDNF) are reduced in the brain and serum of depressed patients and at least the reduction in serum levels is reversible upon successful treatment. These data, together with a wealth of reports using different animal models with depression-like behavior or manipulation of expression of BDNF or its receptor TrkB have implicated BDNF in the pathophysiology of depression as well as in the mechanism of action of antidepressant treatments. Recent findings have shown that posttranslational processing of BDNF gene product can yield different molecular entities that differently influence signaling through BNDF receptor TrkB and the pan-neurotrophin receptor p75(NTR)...
July 15, 2016: Neurobiology of Disease
E M Meylan, L Breuillaud, T Seredenina, P J Magistretti, O Halfon, R Luthi-Carter, J-R Cardinaux
Recent studies implicate the arginine-decarboxylation product agmatine in mood regulation. Agmatine has antidepressant properties in rodent models of depression, and agmatinase (Agmat), the agmatine-degrading enzyme, is upregulated in the brains of mood disorder patients. We have previously shown that mice lacking CREB-regulated transcription coactivator 1 (CRTC1) associate behavioral and molecular depressive-like endophenotypes, as well as blunted responses to classical antidepressants. Here, the molecular basis of the behavioral phenotype of Crtc1(-/-) mice was further examined using microarray gene expression profiling that revealed an upregulation of Agmat in the cortex of Crtc1(-/-) mice...
2016: Translational Psychiatry
Jacob D Meyer, Laura D Ellingson, Kelli F Koltyn, Aaron J Stegner, Jee-Seon Kim, Dane B Cook
: Exercise acutely improves mood in major depressive disorder (MDD). However, it is unknown whether benefits differ depending on whether exercise intensity is self-selected or prescribed. PURPOSE: To compare psychological and biological responses to preferred and prescribed steady-state exercise intensities to a patient-selected preferred intensity. METHOD: Female adults (n = 24, age = 38.6 ± 14.0) diagnosed with MDD completed four, 30-minute session of cycling exercise at three prescribed intensities (rating of perceived exertion [RPE] of 11, 13, 15), and one session with a self-selected intensity (preferred)...
July 6, 2016: Medicine and Science in Sports and Exercise
Rodrigo B Mansur, Camila M Santos, Lucas B Rizzo, Elson Asevedo, Graccielle R Cunha, Mariane N Noto, Mariana Pedrini, Maiara Zeni-Graiff, Quirino Cordeiro, Maj Vinberg, Flavio Kapczinski, Roger S McIntyre, Elisa Brietzke
OBJECTIVES: The neurotrophin brain-derived neurotrophic factor (BDNF) has been proposed as a potential biomarker in bipolar disorder (BD). However, current evidence is limited and results have been highly heterogeneous. This study aimed to assess the moderating effect of impaired glucose metabolism (IGM) on plasma levels of BDNF in individuals with BD, and on the relationship between BDNF and variables of illness course. METHODS: We measured and compared the plasma levels of BDNF in individuals with BD (n=57) and healthy controls (n=26)...
June 2016: Bipolar Disorders
Yin-Yin Bai, Chun-Sheng Ruan, Chun-Rui Yang, Jia-Yi Li, Zhi-Long Kang, Li Zhou, Dennis Liu, Yue-Qing Zeng, Ting-Hua Wang, Chang-Fu Tian, Hong Liao, Larisa Bobrovskaya, Xin-Fu Zhou
Chronic exposure to stressful environment is a key risk factor contributing to the development of depression. However, the mechanisms involved in this process are still unclear. Brain-derived neurotropic factor (BDNF) has long been investigated for its positive role in regulation of mood, although the role of its precursor, proBDNF, in regulation of mood is not known. In this study, using an unpredictable chronic mild stress (UCMS) paradigm we found that the protein levels of proBDNF were increased in the neocortex and hippocampus of stressed mice and this UCMS-induced upregulation of proBDNF was abolished by chronic administration of fluoxetine...
November 2016: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
Ming Li, Hong Chang, Xiao Xiao
Brain-derived neurotrophic factor (BDNF) is a nerve growth factor that has antidepressant-like effects in animal models and may be implicated in the etiology of mood-related phenotypes. A functional polymorphism (Val66Met) in the BDNF gene was demonstrated to influence BDNF's secretion and function, as well as mood and cognitive related phenotypes. However, previous genetic association studies of Val66Met polymorphism in the clinical risk of mood disorders have been complicated, possibly due to phenotypic diversity, underpowered statistical association or ancestry-specific effects...
September 2016: Neuroscience and Biobehavioral Reviews
Katarzyna Młyniec, Gabriela Starowicz, Magdalena Gaweł, Ewelina Frąckiewicz, Gabriel Nowak
Some forms of depression appear to be more related to the glutamatergic system. G-coupled protein receptor 39 (GPR39) is the metabotropic zinc receptor, which may be involved in the pathophysiology of depression and in the antidepressant response. Its deficiency abolishes the antidepressant response, which means that GPR39 is required to obtain a therapeutic effect in depression. This raises the possibility that agonists of the zinc receptor may have a role in antidepressant treatment. To explore this possibility we investigated animal behaviour in the forced swim test, the tail suspension test (to assess antidepressant-like properties), the light/dark test and the elevated plus maze test (to assess anxiolytic-like properties), following acute administration of a GPR39 agonist (TC G-1008)...
September 1, 2016: Journal of Affective Disorders
Amine Bahi
Autism spectrum disorders (ASD) are highly disabling psychiatric disorders. Despite a strong genetic etiology, there are no efficient therapeutic interventions that target the core symptoms of ASD. Emerging evidence suggests that dysfunction of microRNA (miR) machinery may contribute to the underlying molecular mechanisms involved in ASD. Here, we report a stress model demonstrating that neonatal isolation-induced long-lasting hippocampal elevation of miR124a was associated with reduced expression of its target BDNF mRNA...
September 15, 2016: Behavioural Brain Research
Chun-Sheng Ruan, Chun-Rui Yang, Jia-Yi Li, Hai-Yun Luo, Larisa Bobrovskaya, Xin-Fu Zhou
Exposure to stressful life events plays a central role in the development of mood disorders in vulnerable individuals. However, the mechanisms that link mood disorders to stress are poorly understood. Brain-derived neurotrophic factor (BDNF) has long been implicated in positive regulation of depression and anxiety, while its precursor (proBDNF) recently showed an opposing effect on such mental illnesses. P75(NTR) and sortilin are co-receptors of proBDNF, however, the role of these receptors in mood regulation is not established...
July 2016: Experimental Neurology
Li Ren, Weiwei Tao, Hailou Zhang, Wenda Xue, Juanjuan Tang, Ruyan Wu, Baomei Xia, Haoxing Wu, Gang Chen
ETHNOPHARMACOLOGICAL RELEVANCE: Gardenia jasminoides Ellis (GJ) is one of the five constituents of Yueju pill, a Traditional Chinese Medicine for treatment of syndromes associated with mood disorders. Recently, preclinical and clinical studies suggest that Yueju pill confers rapid antidepressant effects. GJ is identified as the constituent primary for Yueju pill's rapid antidepressant effects. GJ's antidepressant action is temporally associated with up-regulated expression of brain-derived neurotrophic factor (BDNF) in the hippocampus...
July 1, 2016: Journal of Ethnopharmacology
Elske T Massolt, Grigoris Effraimidis, Tim I M Korevaar, Wilmar M Wiersinga, W Edward Visser, Robin P Peeters, Hemmo A Drexhage
BACKGROUND: Subjects at risk for major mood disorders have a higher risk to develop autoimmune thyroid disease (AITD) and vice-versa, implying a shared pathogenesis. In mood disorder patients, an abnormal profile of hematopoietic/neuronal growth factors is observed, suggesting that growth/differentiation abnormalities of these cell lineages may predispose to mood disorders. The first objective of our study was to investigate whether an aberrant profile of these hematopoietic/neuronal growth factors is also detectable in subjects at risk for AITD...
2016: PloS One
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"